Post

New research · Ophthalmology
Ocular immunology and inflammation · 13h
StudyOcular immunology and inflammation · 2026

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du, Chen Xing, Zonghui Ma, Zhiyue Zhang
Read paper
OphthalmologyStudy

Brolucizumab shows a massive reporting signal for retinal vasculitis versus other anti-VEGF agents.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du … Zhiyue Zhang
Ocular immunology and inflammation · 2026
Background

The safety profiles of high-dose intravitreal anti-vascular endothelial growth factor (VEGF) agents remain incompletely characterized.

Purpose

This study aimed to compare ocular adverse events, especially intraocular inflammation, associated with brolucizumab, faricimab, and 8 mg aflibercept.

Methods

Adverse event reports for high-dose anti-VEGF agents were extracted from the FDA Adverse Event Reporting System (FDA Adverse Event Reporting System) database.

n = 8,470 reports
Results
ROR = 7,451.51
Reporting odds ratio measures signal strength; higher values mean much more frequently reported than expected.
n = 8,470 reports
More results

Among 8,470 reports where high-dose anti-VEGF agents were designated as primary suspects, intraocular inflammation (intraocular inflammation) was the primary adverse reaction.

“
Conclusion

Intraocular inflammation profiles differ significantly among high-dose anti-VEGF agents. Comprehensive evaluation of individual patients' risk factors is recommended to guide clinical decision-making.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving